- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01271283
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia
Lenalidomide for the Treatment of CLL Patients With High-Risk Disease
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVES:
I. To determine the time to progression in patients with high-risk chronic lymphocytic leukemia (CLL) treated with lenalidomide.
SECONDARY OBJECTIVES:
I. To determine the clinical response (complete and partial response) in treatment-naïve patients with high-risk CLL treated with single-agent lenalidomide.
II. To determine the incidence of immune-mediated flare reaction. III. To determine the toxicity profile of single-agent lenalidomide in previously untreated patients with high-risk CLL.
IV. To conduct correlative studies in bone marrow, peripheral blood, and/or lymph nodes of patients treated with lenalidomide.
OUTLINE:
Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses. Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for correlative studies.
After completion of study therapy, patients are followed up every 3 months for a maximum of 5 years.
Tipo de estudo
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Roswell Park Cancer Institute
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Definitive diagnosis of B-cell chronic lymphocytic leukemia (B-CLL) as defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria
Must have high-risk B-CLL as defined by ≥ one of the following:
- High-risk cytogenetics (either 17p deletion and/or 11q deletion)
- Unmutated immunoglobulin heavy chain gene rearrangement
- Zap-70 and CD38 expression on leukemic cells will not be used as eligibility criteria for enrollment into the clinical trial
- No prior treatment for the management of B-CLL
- Patients must have B-CLL requiring therapy as defined by the IWCLL criteria
Must have measurable disease meeting one of the following criteria:
- Absolute lymphocyte count > 5,000/μL
- Measurable lymphadenopathy or organomegaly
No tumor lysis syndrome (TLS) by Cairo-Bishop definition
- Patients with correction of electrolyte abnormalities allowed
- ECOG performance status 0-2
- ANC ≥ 1,500/mm³
- Platelet count ≥ 75,000/mm³
- Creatinine clearance ≥ 30 mL/min
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST and ALT ≤ 3 times ULN (≤ 5 times ULN if hepatic metastases are present)
Uric acid normal
- Patients with elevated uric acid allowed provided it is corrected with appropriate pharmacologic measures
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must commit to continued abstinence from heterosexual intercourse or use 2 acceptable methods of contraception (1 highly effective method and 1 additional effective method) ≥ 28 days prior to, during, and for ≥ 28 days after discontinuing lenalidomide
- Able to adhere to the study visit schedule and other protocol requirements
- No serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the informed consent form
- No condition, including the presence of laboratory abnormalities, that would place the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- No known hypersensitivity to thalidomide or lenalidomide
- No history of erythema nodosum characterized by a desquamating rash while taking thalidomide or similar drugs
- No history of any other cancer except non-melanoma skin cancer or carcinoma in-situ of the cervix or cancer for which the patient is in complete remission and off therapy for > 3 years
- No cardiac arrest within the past 6 months
- No known history of hepatitis B infection, positive hepatitis B surface antigen, or positive hepatitis C antibody
- No other concurrent anti-cancer agents or treatments
- More than 28 days since any prior experimental drug or therapy
- Aspirin (81 or 325 mg) or warfarin sodium daily as prophylactic anticoagulation required
- No prior lenalidomide
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Arm I
Patients receive oral lenalidomide once daily on days 1-21.
Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity.
Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses.
Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for correlative studies.
|
Estudos correlativos
Dado oralmente
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Time to progression
Prazo: From the start of lenalidomide therapy to time of disease progression, assessed up to 24 months
|
From the start of lenalidomide therapy to time of disease progression, assessed up to 24 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Maximal clinical response (complete and partial response)
Prazo: Up to 24 months
|
Summarized by a sample proportion along with the exact 95% confidence interval.
The time-to-progression will be graphically analyzed using standard Kaplan-Meier estimation.
|
Up to 24 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Neoplasias
- Distúrbios Linfoproliferativos
- Doenças Linfáticas
- Distúrbios imunoproliferativos
- Leucemia de Células B
- Leucemia
- Leucemia Linfocítica Crônica de Células B
- Leucemia Linfóide
- Efeitos Fisiológicos das Drogas
- Agentes Antineoplásicos
- Fatores imunológicos
- Inibidores de angiogênese
- Agentes Moduladores da Angiogênese
- Substâncias de crescimento
- Inibidores de crescimento
- Lenalidomida
Outros números de identificação do estudo
- NCI-2011-02568 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- P30CA016056 (Concessão/Contrato do NIH dos EUA)
- CDR0000692070
- RPCI # I 174910 (Outro identificador: Roswell Park Cancer Institute)
- 8254 (Outro identificador: CTEP)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .